Assessment of AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer

Authors

  • Dr. Yogesh Jadhav
  • Dr. Asitkumar Choudhary
  • Dr. Atul Pawar

DOI:

https://doi.org/10.47750/pnr.2022.13.S03.172

Keywords:

benign prostatic hyperplasia, Gleason Score, Prostate cancer

Abstract

Background: Prostate cancer (PCa) is the second most frequent malignancy in men worldwide. The present study was conducted to assess AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer.

Materials & Methods: 110 patients of suspected benign prostatic hyperplasia (BPH) and PCa were enrolled. Blood samples were collected 1-7 days before surgery. PSA value before biopsy was collected. The upper limit of the reference range, in consideration, was 40 IU/L for AST and 56 IU/L for ALT.

Results: There were 50 cases of PCa and 60 cases of BPH. The mean age was 6.5 years and 67.2 years, BMI (Kg/m2) was 24.1 and 24.6, diabetes was present in 6 and 8, CAD in 10 and 7 and hypertension in 23 and 25 in PCa and BPH patients. The difference was non- significant (P> 0.05). The mean PSA level <10 ng/ml was seen in 12 and 28, >10 ng/ml in 38 and 32, Gleason Score <6 was seen in 11, 7 in 15 and value 8 in 24, mean ALT(IU/L) was 20.1 and 21.6, AST(IU/L) was 20.6 and 19.8 and AST/ALT ratio was 1.14 and 1.21 in PCa and BPH patients respectively. The difference was significant (P< 0.05). Risk factors of prostate cancer was AST/ALT ratio and age. Conclusion: AST/ALT ratio was an independent factor in predicting the incidence of PCa.

Downloads

Published

2022-09-20

Issue

Section

Articles

How to Cite

Assessment of AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. (2022). Journal of Pharmaceutical Negative Results, 1103-1106. https://doi.org/10.47750/pnr.2022.13.S03.172